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Differential diagnosis between childhood onset attention-deficit/hyperactivity disorder (ADHD) 
and bipolar disorder (BD) remains a challenge, mainly due to overlapping symptoms and high 
rates of comorbidity. Despite this, genetic correlation reported for these disorders is low and non-
significant. Here we aimed to better characterize the genetic architecture of these disorders 
utilizing recent large genome-wide association studies (GWAS). We analyzed independent 
GWAS summary statistics for ADHD (19,099 cases and 34,194 controls) and BD (20,352 cases 
and 31,358 controls) applying the conditional/conjunctional false discovery rate 
(condFDR/conjFDR) statistical framework that increases the power to detect novel phenotype-
specific and shared loci by leveraging the combined power of two GWAS. We observed cross-
trait polygenic enrichment for ADHD conditioned on associations with BD, and vice versa. 
Leveraging this enrichment, we identified 19 novel ADHD risk loci and 40 novel BD risk loci at 
condFDR < 0.05. Further, we identified five loci jointly associated with ADHD and BD 
(conjFDR < 0.05). Interestingly, these five loci show concordant directions of effect for ADHD 
and BD. These results highlight a shared underlying genetic risk for ADHD and BD which may 
help to explain the high comorbidity rates and difficulties in differentiating between ADHD and 
BD in the clinic. Improving our understanding of the underlying genetic architecture of these 









Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a 
childhood-onset and a childhood prevalence of approximately 3-5% [1, 2], with the rate of 
persistence into adulthood estimated at 15-65% [3]. ADHD is associated with psychosocial 
disability and societal costs [4]. The most prominent features of ADHD are attentional 
dysfunction, hyperactivity and impulsivity. Affected individuals may also experience additional 
neuropsychological difficulties associated with memory [5], executive functioning [6] and 
emotional dysregulation [7]. In contrast to ADHD, bipolar disorder (BD) has a peak prevalence 
rate in the early 20s and decreases with age thereafter [8]. This disorder affects approximately 
2% of the population when considering both BD I and II types [9]. Moreover, BD is 
characterized by recurrent episodes of mania and depression, affecting thought, perception, 
emotion, cognitive function and social behaviour [8].  
 
Differential diagnosis between ADHD and BD, which relies on clinical observation and 
parental/school reporting, remains a challenge [10, 11]. This is due to factors such as extensive 
symptom overlap, reciprocal comorbidity, as well as the overlapping range in age of onset, 
retrospective parental reports and non-episodic course of BD in youths[10, 11]. It is estimated 
that approximately 20% of adult patients with ADHD have comorbid BD [10], and between 10-
30% of adults affected with BD present with comorbid ADHD [12–14]. This relationship has 
been confirmed in a number of epidemiological, neuroimaging and family studies, however the 
mechanisms behind this association are not fully understood [15].  Given the high heritability of 




explain the high comorbidity rate [18–20]. The complex polygenic nature of these disorders and 
the limited statistical power of the available genetic studies have, however, yet provided no clear 
evidence for genetic overlap.  
 
More recently, a genome-wide cross-disorder meta-analysis of ADHD and BD, using moderately 
powered GWAS samples [21, 22], identified shared risk loci for these disorders [23]. Subsequent 
to these findings, GWAS studies with larger sample sizes and greater statistical power have 
identified many more significant loci for both ADHD [24] and BD [25], however genome-wide 
genetic correlation between these disorders was low and non-significant (rg = 0.095, p = 0.081) 
[24]. One pitfall in the LD-score regression-based estimates of genome-wide genetic correlation 
is that the method relies on consistent effect directions of the overlapping variants for the 
phenotypes of interest [26]. Recent evidence suggests mixed patterns of effect directions for the 
variants shared between diverse phenotype pairs [27–34]. Such patterns may explain the low 
genome-wide genetic correlation identified between ADHD and BD, and thereby highlight the 
usefulness of improved statistical approaches suitable for disentangling the complex genetic 
relationship of these disorders. 
 
The aim of the current study was to investigate the genetic relationship between ADHD and BD 
by applying a conditional/conjunctional false discovery rate (condFDR/conjFDR) approach [35, 
36]. This approach increases the power to detect novel phenotype-specific and shared loci by 
leveraging the combined power of two GWAS, and has been used previously to identify novel 




clinical and epidemiological findings, we hypothesized to discover polygenic overlap as well as 





Methods and Materials 
GWAS Samples 
GWAS summary statistics for ADHD and BD were obtained from the Psychiatric Genomics 
Consortium (PGC). The ADHD sample comprised 19,099 cases and 34,194 controls from 12 
cohorts [24], while the BD sample comprised 32 cohorts with 20,352 cases and 31,358 controls 
[25]. The BD cases included 14,879 individuals with a diagnosis of BD type I (BD1), 3,421 with 
BD type II (BD2), 977 with schizoaffective disorder, bipolar type (SAB), and the remaining with 
unspecified BD [25]. The Norwegian Institutional Review Board for the South-East Norway 
Region has evaluated the current protocol and found that no additional institutional review board 
approval was needed because no individual data were used. More detailed descriptions are 
available in the Supplementary Methods and original publications [24, 25].  
 
Statistical Analyses 
We generated conditional QQ plots in order to visually assess the cross-phenotype polygenic 
enrichment, conditioning ADHD on BD and vice versa. QQ plots depict the quantiles of the 
observed p-values on the y-axis against the theoretical quantiles under no association on the x-
axis. Such QQ plots follow a straight line in the case of no association, but deflect from this line 
when some form of systematic association is present. Conditional QQ plots depict the differential 
enrichment between pre-specified strata of single nucleotide polymorphisms (SNPs). The data 
points on the QQ plot are weighted according to the LD structure around the corresponding SNP. 
We used n=200 iterations of random pruning with an LD threshold r2=0.1 to define LD-blocks 




contribute to the p-value distribution statistics. The procedure entails the selection of a primary 
trait (e.g. ADHD) and the definition of SNP strata based on a secondary conditional trait (e.g. 
BD). We plotted the SNP p-values of the primary trait conditional on different strengths of 
association with the secondary trait (i.e. −log10 p- values > 1, 2, or 3). This enabled us to 
determine if conditioning on a secondary trait leads to stronger association in the primary trait. A 
stronger enrichment together with increased evidence for association with the secondary trait can 
be an indicator of a shared polygenic architecture between the two traits. As a means for 
comparison, we also estimated the genetic correlation between these ADHD and BD samples 
[26, 42].  
 
To identify shared loci between ADHD and BD we employed the condFDR/conjFDR method 
[35, 36]. The condFDR method utilizes genetic association summary statistics from a trait of 
interest (ADHD) together with those of a conditional trait (BD) to estimate the posterior 
probability that a SNP has no association with the primary trait, given that the p-values for that 
SNP in both the primary and conditional traits are lower than the observed p-values. This method 
increases the power to identify loci associated with the primary trait by leveraging associations 
with conditional traits, thereby re-ranking SNPs compared to the original GWAS p-value 
ranking. The conjFDR statistic is defined as the maximum of the two mutual condFDR values 
and is a conservative estimate of the posterior probability that a SNP has no association with 
either trait, given that the p-values for that SNP in both the primary and conditional traits are 
lower than the observed p-values. The conjFDR method thus allows the identification of loci 
associated with both traits. An FDR level of 0.05 per pair-wise comparison was set for condFDR 




[35]. All code used for carrying out the described analyses is available online 
(https://github.com/precimed/pleiofdr). More details about the condFDR/conjFDR methods can 
be found in the original and subsequent publications [27, 29, 32, 35–41, 43], and the 
Supplementary Methods.  
 
Genomic loci definition 
Independent genomic loci were defined according to the FUMA protocol [44]. First independent 
significant SNPs were identified as SNPs with condFDR/conjFDR < 0.05 and linkage 
disequilibrium (LD) r2 < 0.6 with each other. A subset of these SNPs (LD r2 < 0.1) were then 
selected as lead SNPs. The borders for genomic loci were then defined by identifying all 
candidate SNPs in LD (r2 ≧ 0.6) with a lead SNP. Loci were merged if they were separated by 
less than 250 kb. These distinct regions, containing all of these candidate SNPs, were considered 
to be a single independent genomic locus. All LD information was calculated from the 1000 
Genomes Project reference panel [45]. Novel risk loci were defined as those not identified 
(separated by at least 250 kb) in the original GWAS samples used for these analyses [24, 25] and 
not identified as risk loci for ADHD or BD in previous studies. 
 
Functional annotation 
Positional and functional annotation of all candidate SNPs, in the genomic loci with a conjFDR 
value < 0.10 having an LD r2 ≧ 0.6 with one of the independent significant SNPs, was performed 
using ANNOVAR [46], implemented in FUMA [44]. SNPs were also annotated with Combined 
Annotation Dependent Depletion (CADD) [47] scores, which predict how deleterious the SNP 




regulatory functionality, and chromatin states, which predict transcription/regulatory effects from 
chromatin states at the SNP locus [49, 50]. We also identified previously reported GWAS 
associations in the NHGRI-EBI catalog [51] overlapping with the identified loci. Finally, we 
queried SNPs for known expression quantitative trait loci (eQTLs) in the genotype tissue 
expression (GTEx) portal [52].  
 
Evaluation of identified loci in an independent ADHD case-control cohort 
To assess the robustness of the condFDR/conjFDR results we examined the most significant 
SNPs in the identified loci in the association summary statistics from a case-control ADHD 
cohort from deCODE Genetics (n = 10,217 cases, n = 338,344 controls). A description of this 
cohort is provided in the Supplementary Methods. In order to compare SNP effect directions, 
sign concordance was determined between the PGC ADHD GWAS [24] and deCODE cohorts.  
 
Results 
Genetic Overlap and Correlation 
The conditional QQ plots suggest the presence of enrichment for ADHD given BD (Figure 1A), 
shown by the incremental incidence of association with ADHD (leftward deflection) as a 
function of the significance of association with BD. Similar and even more marked results are 
observed for the reverse relationship, BD conditioned on ADHD (Figure 1B). The LD score 
regression analysis is in line with the enrichment showing a positive genetic correlation between 





We leveraged this cross-phenotype polygenic enrichment using condFDR analyses and re-ranked 
ADHD SNPs conditionally on their association with BD, and vice versa. At condFDR < 0.05 we 
identified 33 loci associated with ADHD after conditioning on BD (Supplementary Figure 1, 
Supplementary Table 1), 19 of which are novel ADHD-risk loci (Table 1). When considering the 
allelic effect direction for the 33 lead SNPs in these ADHD-risk loci, 23 have concordant 
direction of effect with BD (Supplementary Table 1). Functional annotation of the 19 novel 
ADHD-risk loci revealed that the majority are intergenic or intronic (Table 1). One lead SNP 
(rs992936, CADD = 20.5) has a CADD score above the threshold score of 12.37, suggestive of 
deleteriousness [47] (Supplementary Table 1). After querying the GTEx portal [52], five lead 
SNPs were identified as potential eQTLs for various tissues (Supplementary Table 2). Three 
were identified as eQTLs for genes within at least one brain region (Supplementary Table 2). 
 
The inverse conditional analysis identified 94 loci associated with BD after conditioning on 
ADHD (Supplementary Figure 1, Supplementary Table 3), 40 of which are novel BD-risk loci 
(Table 2). When considering the allelic effect direction for the 94 lead SNPs in these BD-risk 
loci, 56 have concordant direction of effect with ADHD (Supplementary Table 3). Functional 
annotation revealed the majority of the 40 novel BD-risk loci to be intergenic or intronic (Table 
2). Five lead SNPs were reported to have a CADD score greater than 12.37, suggestive of 
deleteriousness [47], and three lead SNPs reported low RDB scores (1f, 2a and 2b) indicative of 
regulatory functionality [48] (Supplementary Table 3). Querying the GTEx portal [52] for these 
novel BD-risk loci identified 12 lead SNPs as potential eQTLs for genes in at least one brain 
tissue (Supplementary Table 4). Further, 29 of the identified BD-risk loci overlap with lead SNPs 




while none of the BD-risk loci overlap with lead SNPs from the analyses of bipolar II disorder or 
schizoaffective disorder–bipolar type (Supplementary Table 3) [25]. 
 
A total of five loci were jointly associated with ADHD and BD at conjFDR < 0.05 (Figure 2, 
Supplementary Table 5). Two of these loci (lead SNP rs323509, 5:103671867-104082179 and 
lead SNP rs11167721, 5:154772692-154984679) are novel risk loci for both ADHD and BD 
(Table 3), i.e. these loci were not identified in the original GWAS studies [24, 25] and not 
implicated in these disorders by previous studies. One shared locus (lead SNP rs11936939, 
4:101463177-101593148) was novel for ADHD, but not BD. Two of these novel shared loci 
were included in the GWAS catalog due to reported associations with anorexia nervosa [53] and 
depression [54], and cognitive decline [55], respectively. Furthermore, all five shared loci have 
concordant effects on ADHD and BD risk (Supplementary Table 5), and none of these loci 
overlap with lead SNPs from the analyses of bipolar I disorder, bipolar II disorder or 
schizoaffective disorder–bipolar type (Supplementary Tables 3 and 5) [25]. 
 
Functional annotation of all SNPs with conjFDR < 0.1 within the loci shared between ADHD 
and BD revealed that all candidate SNPs (n=73) are intronic or intergenic (Supplementary Table 
6). Of these 73 candidate SNPs, three SNPs (rs2431108, rs13162928, rs1956002) reported 
CADD scores above the 12.37 threshold score suggestive of deleteriousness [47]. After querying 
the GTEx portal [52], ten candidate SNPs, all within the same genomic locus, were identified as 
potential eQTLs for the RP11-6N13.1 gene in the testis (Supplementary Table 7). Gene-set and 




(Supplementary Table 6 revealed no significantly enriched biological processes, cellular 
components or molecular functions. 
 
Evaluation of identified loci in an independent ADHD case-control cohort 
Of the five loci shared between ADHD and BD (conjFDR < 0.05), lead SNPs within four of 
these loci showed concordant effect direction between the PGC GWAS and deCODE cohorts 
(Supplementary Table 5). Moreover, when considering all candidate SNPs within these five loci, 
46/73 showed concordant direction of effect (Supplementary Table 6). For the ADHD-risk loci 
identified by conditioning on BD (condFDR < 0.01), 19/33 of the lead SNPs within these loci 
were concordant in the deCODE cohort (Supplementary Table 1). The concordance rates were 
similar for the ADHD-risk loci previously identified in the PGC ADHD GWAS [24] (7/12 
concordant lead SNPs), and the additional ADHD-risk loci identified in the present study (12/21 
concordant lead SNPs).  
 
Discussion 
The current study identified novel ADHD and BD associated risk loci, as well as novel genetic 
loci shared between these disorders, by applying the condFDR/conjFDR method to GWAS 
summary statistics [24, 25]. The results provide further evidence for a shared polygenic 
architecture between ADHD and BD, and therewith potential new insight into the molecular 
mechanisms that may explain the high comorbidity rates and shared phenotypes between these 





We observed cross-trait polygenic enrichment between ADHD and BD using conditional QQ 
plots (Figure 1), supporting recent genetic evidence [23] and prior epidemiological, 
neuroimaging and family studies [15]. This observed enrichment was supported by significant 
positive genome-wide genetic correlation identified in this study (rg 0.121, SE 0.038, p = 0.002). 
Leveraging this enrichment, we used the condFDR approach to identify 19 novel risk loci for 
ADHD (Table 1) and 40 novel risk loci for BD (Table 2). Expanding on our condFDR results, 
we identified five risk loci shared by ADHD and BD using the conjFDR method (Table 3), two 
of which are novel risk loci for both disorders (lead SNP rs323509, 5:103671867-104082179 and 
lead SNP rs11167721, 5:154772692-154984679). Remarkably, when considering the identified 
genetic correlation, all of the lead and candidate SNPs within the five loci jointly associated with 
ADHD and BD show concordant direction of effect for these disorders (Supplementary Table 6). 
The identification of polygenic overlap between ADHD and BD, that includes agonistic SNP 
effects, may have important clinical implications. These results highlight a shared underlying 
genetic risk for ADHD and BD that remains to be fully characterized. Specific symptoms and/or 
clinical observations common to the diagnostic criteria for these disorders may have the same 
genetic causes, which may help to explain the high comorbidity rates [10, 12, 13] and difficulties 
in differential diagnosis between ADHD and BD [10, 11]. Although the shared genetic loci 
identified in this study all had concordant effect directions, and thus may not be useful for 
stratifying between ADHD and BD affected patients, they may aid the development of novel 
genetic prediction tools to identify patients at risk of comorbid ADHD and BD. Moreover, an 
improved understanding of the overlapping and discrete genetic components underlying these 
disorders may aid in the development of novel stratification tools to help reduce the difficulty in 




To further evaluate the shared and ADHD-associated loci, identified utilizing the data from the 
PGC ADHD GWAS, we examined the lead and candidate SNPs in an independent ADHD case-
control sample. Four of the five shared loci showed consistent direction of effect in the 
independent ADHD sample (Supplementary Table 5). In addition, the majority of candidate 
SNPs (46/73) within these shared loci showed similarly concordant effect direction, with similar 
concordance rates as described in the original PGC ADHD GWAS [24]. 
 
We identified 33 ADHD-associated risk loci after conditioning ADHD on BD. These include the 
12 loci reported in the initial GWAS [24], two loci attributed to ADHD in previous studies 
(Supplementary Table 1) and 19 novel risk loci (Table 1). Similarly, after conditioning BD on 
ADHD, we identified 94 BD-associated risk loci. The original BD study reported 19 significant 
loci in a discovery phase GWAS (data we have used in this study) and 30 significant loci in a 
combined GWAS including the discovery and a replication sample. Amongst the BD-associated 
loci identified in this study (Supplementary Table 3), we replicated the 19 loci identified in the 
discovery phase of the original GWAS [25], as well as 15 loci only identified in the combined 
analysis [25]. In addition, we identified 21 loci attributed to BD in previous studies 
(Supplementary Table 3), and identify a further 40 novel BD-associated risk loci (Table 2). 
These results highlight how the condFDR approach can be used to exploit GWAS summary 
statistics for improved power for loci discovery.  
 
Further analysis of the novel ADHD-associated risk loci suggests that six lead SNPs may 
function as eQTLs for a number of genes in numerous tissue types (Supplementary Table 2). 




of nine genes in specific brain tissues, including the caudate basal ganglia, cerebellar 
hemisphere, cerebellum, cortex, frontal cortex BA9 and anterior cingulate cortex BA24. Among 
these differentially expressed genes, three (CD40, MANBA, LRRC37A15P) were recently 
identified as likely causal genes for ADHD [56], increasing confidence that these genes play 
some role in the etiology of the disorder. Both the CD40 [57] and MANBA [58] genes encode 
proteins involved in the immune system providing further evidence for the hypothesis that 
dysfunction of the immune system may modulate risk of psychiatric disorders [59]. In addition, 
four of these genes (GPX1, AMT, RNF123, INKA1) are listed in the GWAS catalog for 
associations with general intelligence and educational attainment [51], two phenotypes linked 
with ADHD in epidemiological, clinical and genetic studies [37, 60–64], suggesting that these 
genes may play a role in brain networks involved in behavior and cognition.  
 
A similar eQTL analysis of the lead SNPs for the novel BD-associated risk loci identified 28 
SNPs that alter the expression of 68 genes in numerous tissue types (Supplementary Table 4). Of 
these, 12 SNPs were identified as eQTLs for 19 genes within 13 specific brain tissues 
(Supplementary Table 4). Three SNPs (rs11917269, rs2843728, rs4886883) were identified as 
eQTLs for the HYAL3 (Cortex), PLPP5 (Cerebellum) and LINGO1 (Putamen) genes, 
respectively (Supplementary Table 4). These genes are indexed in the GWAS catalog for 
associations with schizophrenia and autism spectrum disorder, as well as general intelligence 
[51], highlighting their potential involvement in psychiatric and cognitive phenotypes. 
Interestingly, SNP rs4820214 was also identified as an eQTL for the TOP3B (Cortex, frontal 




cervical c-1) and PPM1F (Putamen) genes, all of which were previously implicated with ADHD 
risk in the GWAS catalog [51]. 
 
One limitation of the condFDR/conjFDR approach is that it is sensitive to LD-biases intrinsic to 
the association p-values. The genetic variants with more correlations to their neighbours are 
more likely to tag any causal variants than more isolated variants and this could result in slightly 
inflated FDR estimates. Another limitation this method inherits from the GWAS it draws upon is 
that it is agnostic with regard to the specific causal variants underlying the overlapping genomic 
loci. These overlapping loci could result from both shared or separate causal variants, or 
“mediated pleiotropy”, where one phenotype is causative of the other [65]. Further, since the 
cross-trait enrichment reflects the extent of polygenic overlap between the phenotypes as well as 
the power of the two GWAS samples analyzed, this enrichment will be more difficult to detect if 
the utilized GWAS samples are inadequately powered.  
 
The current findings of shared genetic loci between ADHD and BD may suggest that there are 
overlapping clinical features between ADHD and BD, suggesting that subgroups of patients with 
mixed clinical features could benefit from specific interventions. In addition, it should be noted 
that there is a possibility that our findings of shared genetic loci between ADHD and BD may be 
the result of bias from misdiagnosis in the original GWAS studies [24, 25], i.e., that ADHD 
patients were misdiagnosed as BD, or vice versa. The number of such cases is estimated to be 
small due to the inclusion/exclusion criteria employed in these studies [24, 25], the low genetic 
correlation between these samples (rg 0.121), and the low prevalence of the disorders. At any 




future GWAS to more accurately determine the specific genetic architecture of these complex 
traits across current nosological categories [66, 67].  
 
Moreover, another possible limitation to this study is the over-representation of BD1 (73%) in 
the BD GWAS, when compared to BD2 (17%) and SAB (5%) [25]. Although none of the shared 
loci between ADHD and BD overlapped with lead SNPs from the analyses of these BD-
subtypes, a number of the identified BD-risk loci were shown to overlap with lead SNPs from 
the BD1 analysis (Supplementary Tables 3 and 5) [25]. This indicates a potential bias of the loci 
reported in this study to be more specific to BD1 and highlights the need to better clarify the 
genetic architecture of these BD-subtypes, when larger, well-powered samples become available. 
Finally, we show validation of the identified shared and ADHD-associated loci in an independent 
ADHD sample. Due to the smaller sample size of cases in this independent ADHD cohort, we 
were not able to perform true replication analyses using the condFDR/conjFDR method. An 
independent BD sample was not available for similar assessment. These results highlight the 
need to replicate the loci identified in this study in large well-powered independent cohorts and 
additional experimental work is needed in order to establish the functional implications of these 
loci and the reported tag SNPs.  
 
In conclusion, we observed polygenic enrichment and identified five shared loci between ADHD 
and BD that may help to explain the underlying mechanisms behind the high rates of 
comorbidity observed for these disorders [12, 13, 15]. We leveraged this genetic overlap and 
identified 20 novel ADHD-risk loci and 53 novel BD-risk loci, and 4 loci associated with both 




correlation have clinical implications, suggesting genetic factors underlying the comorbidity and 
overlapping phenotypes between ADHD and BD.  
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Figure 1. Conditional QQ plots showing cross-phenotype polygenic enrichment between 
attention deficit/hyperactivity disorder (ADHD) and bipolar disorder (BD). Plotted are the 
nominal vs empirical −log10 p-values (corrected for inflation) for the trait of interest, below the 
standard genome-wide association study threshold of p < 5.0 × 10−8, as a function of significance 
of association with the conditional trait at the level of p ≤ 0.10, p ≤ 0.01 and p ≤ 0.001. The 
dashed lines indicate the null hypothesis. (A) ADHD is the trait of interest and is conditioned on 
BD. (B) BD is the trait of interest and is conditioned on ADHD.  
 
Figure 2. Common genetic variants jointly associated with attention deficit/hyperactivity 
disorder (ADHD) and bipolar disorder (BD) at conjunctional false discovery rate (conjFDR) < 
0.05. Manhattan plot showing the –log10 transformed conjFDR values for each SNP on the y-
axis and chromosomal positions along the x-axis. The dotted horizontal line represents the 
threshold for significant shared associations (conjFDR < 0.05). Independent lead SNPs are 
encircled in black, and are annotated to the nearest gene. Further details for these shared loci are 
provided in Supplementary Table 5 and 7. * Loci previously identified for ADHD [24, 68] 




Table 1. Novel genomic loci associated with attention deficit/hyperactivity disorder (ADHD) 




















3 1 rs2391769 A/G EEF1A1P11 intergenic 1.038E-07 0.928 2.923E-01 0.985 1.972E-02 
6 3 rs28535523 C/T UBA7 intronic 8.248E-06 1.079 2.750E-03 1.053 2.564E-02 
8 4 rs1484144 T/C LINC01088:NAA11 ncRNA_intronic 1.984E-06 1.066 7.564E-03 1.037 1.664E-02 
9 4 rs11936939 C/T EMCN intergenic 1.371E-05 0.941 1.193E-04 0.948 1.302E-02 
10 4 rs227280 A/G MANBA intronic 7.050E-08 0.924 6.491E-01 1.007 2.650E-02 
12 5 rs12658032 A/G RP11-6N13.1 ncRNA_intronic 1.154E-07 1.078 2.685E-04 1.053 2.340E-04 
13 5 rs11167721 C/T CTC-447K7.1 intergenic 8.348E-05 1.063 9.093E-05 1.062 4.832E-02 
14 6 rs141547796 G/A RP1-28O17.1 intergenic 9.640E-08 0.872 6.753E-01 1.011 3.297E-02 
17 7 rs2218378 A/G CADPS2 intronic 2.048E-07 0.929 6.246E-01 0.993 4.860E-02 
19 8 rs72673548 T/C RP11-700E23.3 intergenic 1.163E-06 0.891 2.149E-02 0.946 2.112E-02 
20 10 rs713240 C/T ARID5B intronic 3.357E-06 1.065 2.080E-02 0.969 4.178E-02 
22 11 rs10835362 G/A RP11-960D24.1 intergenic 5.379E-07 0.933 4.501E-02 0.973 1.902E-02 
24 14 rs4981170 A/G NPAS3 intronic 1.298E-05 0.925 9.819E-05 0.933 1.245E-02 
26 15 rs60798171 T/G RP11-138H10.2 intergenic 7.250E-07 0.925 4.300E-02 0.968 2.275E-02 
28 16 rs1436380 A/G CDH8 intronic 3.710E-06 0.938 2.257E-04 0.951 4.531E-03 
30 18 rs4144756 G/A RP11-188I24.1 intergenic 1.455E-07 1.080 5.966E-01 1.008 3.858E-02 
31 18 rs17084232 C/T RP11-47G4.2 intergenic 1.703E-07 1.195 2.531E-01 0.961 2.476E-02 
32 20 rs6032660 G/A RPL13P2 intergenic 1.361E-05 0.934 8.940E-04 0.950 2.006E-02 
33 21 rs992936 T/C NEK4P1 intergenic 1.783E-07 1.074 2.716E-01 1.015 2.658E-02 
The most strongly associated SNPs in novel genomic loci associated with ADHD at 
condFDR<0.05 given association with BD after merging regions < 250 kb apart into a single 
locus. The table presents chromosomal position (Chr), nearest gene and functional category, 
as well as p-values and effect sizes (odds ratios) from the original summary statistics on 
ADHD 26 and BD 27. The effect sizes are given with reference to allele 2 (A2). For more 
details and the full list of all loci associated with ADHD at condFDR<0.05, see 




Table 2. Novel genomic loci associated with bipolar disorder (BD) at conditional FDR 




















1 1 rs1278516 G/A RP5-850O15.4 intergenic 5.558E-07 0.893 2.745E-02 1.049 8.622E-03 
3 1 rs12563424 T/C TMEM56 intergenic 5.293E-07 0.933 9.061E-02 0.977 1.796E-02 
5 1 rs80148877 T/C RP4-640E24.1 intergenic 1.092E-06 0.860 1.495E-01 1.045 3.618E-02 
6 1 rs4652746 G/A AL513344.1 intergenic 1.458E-06 1.096 8.772E-02 1.034 3.168E-02 
7 1 rs7550853 A/C SMYD3 intronic 1.499E-05 0.936 1.176E-02 0.962 4.128E-02 
8 2 rs5015511 G/A AC068490.2 ncRNA_intronic 1.122E-04 1.054 1.095E-04 1.057 3.928E-02 
14 2 rs12621381 A/C snoU13 intergenic 9.798E-07 0.934 4.141E-03 0.962 3.756E-03 
18 3 rs11917269 G/T CACNA2D2 intronic 1.322E-06 0.926 8.249E-03 0.958 7.084E-03 
20 3 rs3774608 G/A CACNA1D intronic 7.716E-06 0.940 1.068E-02 1.036 2.604E-02 
21 3 rs62252499 A/G CADM2 intronic 7.247E-05 1.063 1.557E-03 1.045 4.577E-02 
23 3 rs6767302 A/G HMGN2P25 downstream 2.123E-07 1.073 4.113E-01 1.011 2.796E-02 
24 3 rs55657715 A/G ATP11B intronic 6.111E-05 0.945 1.254E-03 1.047 3.741E-02 
26 4 rs6829845 A/G IL21 intergenic 2.940E-07 1.076 9.240E-03 0.964 2.756E-03 
30 5 rs7707252 A/G Y_RNA intergenic 2.987E-05 0.940 3.143E-04 1.056 1.386E-02 
32 5 rs323509 A/C RP11-6N13.1 ncRNA_intronic 8.940E-06 1.067 1.655E-06 1.073 5.345E-03 
35 5 rs9324815 A/G CTC-447K7.1 downstream 2.516E-05 0.942 3.118E-04 0.950 1.214E-02 
42 7 rs6947663 G/A AC007652.1 ncRNA_intronic 3.947E-05 0.943 4.002E-03 1.043 4.494E-02 
43 7 rs12538191 G/A RP4-647J21.1 intergenic 1.461E-07 0.909 9.158E-02 1.033 8.453E-03 
45 7 rs73147614 G/A SMURF1 intronic 3.544E-05 0.838 4.694E-03 1.108 4.515E-02 
50 8 rs2843728 C/T RP11-90P5.2 ncRNA_intronic 2.918E-06 0.934 1.272E-02 0.965 1.545E-02 
51 8 rs10505139 A/G RP11-403P13.1 intergenic 6.337E-07 0.915 1.940E-01 0.977 3.115E-02 
52 8 rs57957974 C/A PARP10 intronic 4.977E-07 1.076 2.120E-01 1.018 2.881E-02 
53 9 rs57298275 T/C ANP32B intronic 3.392E-05 1.060 7.689E-04 1.047 1.993E-02 
54 9 rs113314512 G/A RP11-6F6.1 intergenic 3.268E-05 1.174 3.734E-03 1.133 3.871E-02 
55 9 rs10120508 G/A RP11-295D22.1 intergenic 9.078E-07 0.930 2.475E-01 1.018 4.293E-02 
56 10 rs7915021 C/T ST8SIA6 intronic 6.859E-07 0.906 9.293E-02 0.967 2.119E-02 
68 12 rs17680262 C/T TCHP UTR3 6.714E-06 1.115 2.196E-02 0.945 3.553E-02 
69 14 rs72673100 C/A LINC00641 ncRNA_exonic 1.769E-06 0.931 1.134E-01 0.974 4.068E-02 
74 15 rs4886883 A/G RP11-307C19.2 ncRNA_intronic 1.604E-05 0.942 5.222E-03 1.040 2.862E-02 
77 16 rs58867145 C/T RP11-266L9.5 intergenic 2.192E-05 1.073 1.087E-03 1.059 1.676E-02 
78 16 rs976498 C/T RP11-439I14.2 intergenic 6.602E-07 1.098 1.721E-01 1.025 2.971E-02 
79 16 rs10492859 A/G CDH13:RP11-22H5.2 ncRNA_intronic 4.454E-06 1.076 4.385E-02 1.033 4.101E-02 
80 17 rs2302776 A/G MED24 intronic 9.222E-07 1.070 2.283E-01 1.017 4.144E-02 
81 17 rs7217151 C/T UTP18 intronic 4.378E-07 1.071 3.532E-01 1.013 3.618E-02 
84 19 rs3843751 C/T SLC44A2 intronic 1.602E-07 1.079 1.996E-01 0.981 1.508E-02 
86 19 rs56332086 C/T ZNF584 ncRNA_exonic 2.753E-05 0.930 7.121E-03 0.957 4.668E-02 
90 20 rs12624433 G/A SLC12A5 intronic 7.448E-05 1.063 1.056E-03 1.052 4.036E-02 
91 20 rs1850 T/C RP5-955M13.4:KCNG1 ncRNA_intronic 1.490E-07 0.927 6.569E-01 1.006 3.202E-02 
92 20 rs6090435 G/A RP4-697K14.3 upstream 4.393E-07 0.927 4.019E-01 0.988 3.907E-02 
93 22 rs4820214 C/T KB-1027C11.4 intergenic 6.717E-07 0.935 1.154E-01 0.978 2.383E-02 
 The most strongly associated SNPs in novel genomic loci associated with BD at 
condFDR<0.05 given association with ADHD after merging regions < 250 kb apart into a 
single locus. The table presents chromosomal position (Chr), nearest gene and functional 
category, as well as p-values and effect sizes (odds ratios) from the original summary 
statistics on BD 27 and ADHD 26. The effect sizes are given with reference to allele 2 (A2). 
For more details and the full list of all loci associated with BD at condFDR<0.05, see 
Supplementary Table 3. 
 
Table 3. Novel loci jointly associated with attention deficit/hyperactivity disorder (ADHD) 




















1 4 rs11936939 C/T EMCN* intergenic 1.371E-05 0.941 1.193E-04 0.948 4.023E-02 
2 5 rs323509 A/C RP11-6N13.1 ncRNA_intronic 1.655E-06 1.073 8.940E-06 1.067 5.027E-03 
3 5 rs11167721 C/T CTC-447K7.1 intergenic 8.348E-05 1.063 9.093E-05 1.062 4.832E-02 
 The most strongly associated SNPs in independent genomic loci shared between ADHD and 
BD at conjFDR<0.05 after merging regions < 250 kb apart into a single locus. The table 
presents chromosomal position (Chr), nearest gene and functional category, as well as p-
values and effect sizes (odds ratios) from the original summary statistics on ADHD 26 and BD 
27. The effect sizes are given with reference to allele 2 (A2). For more details and a list of all 
candidate variants in these loci, see Supplementary Table 6 and 7. * Novel for ADHD only. 
 
